**Supplementary Table**: percentage of patients monitored at least once before and during glucocorticoid exposure according to the underlying disease and the duration of exposure

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Asthma | COPD | Rheumatoid arthritis | Inflammatory bowel diseases | Polymyalgia rheumatica/giant cell arteritis |
|  | 3-12 monthsn=9804 | > 12 monthsn=1915 | 3-12 monthsn=9277 | > 12 monthsn=1979 | 3-12 monthsn=3046 | > 12 monthsn=2289 | 3-12 monthsn=3910 | > 12 monthsn=548 | 3-12 monthsn=12643 | > 12 monthsn=10099 |
| **Weight** before exposureduring exposure | 1999 (20.4%)2453 (25.0%) | 487 (25.4%)1220 (63.7%) | 2082 (22.4%)2699 (29.1%) | 452 (22.8%)1241 (62.7%) | 588 (19.3%)744 (24.4%) | 465 (20.3%)1273 (55.6%) | 925 (23.7%)955 (24.4%) | 148 (27.0%)282 (51.5%) | 2423 (19.2%)3628 (28.7%) | 1961 (19.4%)5697 (56.4%) |
| **Blood pressure** before exposureduring exposure | 3542 (36.1%)4366 (44.5%) | 836 (43.7%)1666 (87.0%) | 3816 (41.1%)4990 (53.8%) | 836 (42.2%)1728 (87.3%) | 1140 (37.4%)1485 (48.8%) | 917 (40.1%)1952 (85.3%) | 1078 (27.6%)1294 (33.1%) | 196 (35.8%)384 (70.1%) | 6345 (50.2%)8274 (65.4%) | 5119 (50.7%)9078 (89.9%) |
| **Fasting glycemia**before exposureduring exposure | 1704 (17.4%)2097 (21.4%) | 439 (22.9%)1174 (61.3%) | 1821 (19.6%)2345 (25.3%) | 402 (20.3%)1204 (60.8%) | 631 (20.7%)681 (22.4%) | 473 (20.7%)1282 (56.0%) | 551 (14.1%)618 (15.8%) | 91 (16.6%)252 (46.0%) | 4563 (36.1%)4620 (36.5%) | 3646 (36.1%)6902 (68.3%) |
| **Kalemia**before exposureduring exposure | 2423 (14.7%)2836 (28.9%) | 642 (33.5%)1433 (74.8%) | 2616 (28.2%)3312 (35.7%) | 647 (32.7%)1473 (74.4%) | 1501 (49.3%)1672 (54.9%) | 1075 (47.0%)1935 (84.5%) | 1396 (35.7%)1530 (39.1%) | 166 (30.3%)386 (70.4%) | 7129 (56.4%)6094 (48.2%) | 5785 (57.3%)8044 (79.7%) |
| **Lipids**before exposureduring exposure | 3193 (32.6%)1494 (15.2%) | 675 (35.3%)1041 (54.4%) | 3830 (41.3%)1787 (19.3%) | 732 (37.0%)1045 (52.8%) | 996 (32.7%)544 (17.9%) | 707 (30.9%)1120 (48.9%) | 681 (17.4%)351 (9.0%) | 116 (21.2%)184 (33.6%) | 6192 (49.0%)3336 (26.4%) | 4829 (47.8%)5784 (57.3%) |
| **DXA-scan**before exposureduring exposure | 986 (10.1%)389 (4.0%) | 231 (12.1%)447 (23.3%) | 920 (9.9%)369 (4.0%) | 220 (11.1%)376 (19.0%) | 439 (14.4%)236 (7.8%) | 362 (15.8%)577 (25.2%) | 385 (9.9%)196 (5.0%) | 51 (9.3%)116 (21.2%) | 1998 (15.8%)918 (7.3%) | 1713 (17.0%)2225 (22.0%) |
| **Eye survey**before exposureduring exposure | 1053 (10.7%)373 (3.8%) | 229 (12.0%)432 (22.6%) | 1273 (13.7%)446 (4.8%) | 265 (13.4%)479 (24.2%) | 277 (9.1%)149 (4.9%) | 193 (8.4%)475 (20.8%) | 218 (5.6%)72 (1.8%) | 43 (7.9%)87 (15.9%) | 2029 (16.1%)1192 (9.4%) | 1536 (15.2%)2480 (24.6%) |
| **Flu vaccine**before exposureduring exposure | 6410 (65.4%)2825 (28.8%) | 1264 (66.0%)1639 (85.6%) | 7306 (78.8%)3132 (33.8%) | 1484 (75.0%)1772 (89.5%) | 1393 (45.7%)996 (32.7%) | 1077 (47.1%)1746 (76.3%) | 981 (25.1%)632 (16.2%) | 177 (32.3%)322 (58.8%) | 8359 (66.1%)5167 (40.9%) | 6769 (67.0%)8177 (81.0%) |
| **Pneumococcal vaccine**before exposureduring exposure\* | 5198 (53.0%)263 (5.7%) | 1120 (58.5%)244 (30.7%) | 6805 (73.4%)245 (9.9%) | 1397 (70.6%)215 (36.9%) | 994 (32.6%)139 (6.8%) | 784 (34.3%)492 (32.7%) | 567 (14.5%)87 (2.6%) | 118 (21.5%)78 (18.1%) | 6548 (51.8%)442 (7.3%) | 5311 (52.6%)4788 (29.6%) |

\* the patients vaccinated before glucocorticoid initiation were excluded